tiprankstipranks
Tiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer’s
PremiumThe FlyTiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer’s
1M ago
Tiziana Life Sciences announces updated clinical, PET scan findings
PremiumThe Fly
Tiziana Life Sciences announces updated clinical, PET scan findings
3M ago
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
PremiumPress Releases
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
3M ago
Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab
PremiumThe FlyTiziana Life doses first patient in Phase 2a trial of intranasal foralumab
4M ago
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
PremiumPress Releases
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
5M ago
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
PremiumPress Releases
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
5M ago
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
PremiumPress ReleasesTiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
6M ago
Tiziana Life Sciences announces six-month PET scan results with foralumab
PremiumThe Fly
Tiziana Life Sciences announces six-month PET scan results with foralumab
6M ago
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
PremiumPress Releases
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100